{
    "nctId": "NCT05738993",
    "briefTitle": "A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta\u00ae in Healthy Volunteers",
    "officialTitle": "A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta\u00ae in Healthy Volunteers",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "AUC0-\u221e",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent;\n* Men aged 18-45 years;\n* Body mass index (BMI) in the range of 18.5 30.0 kg/m2;\n* The confirmed \"healthy\" status;\n* Left ventricular ejection fraction (LVEF) \\> 50 % based on the results of EchoCG at screening;\n* Willingness of the volunteers and their sexual partners of childbearing potential to use reliable methods of contraception, starting from signing the informed consent form, during the study, and for 6 months after the drug administration;\n\nExclusion Criteria:\n\n* Known allergy or intolerance to monoclonal antibody products (murine, chimeric, humanized, fully human) or any other components of the study drugs;\n* Values of standard laboratory and instrumental parameters exceeding the normal limits accepted at the study site;\n* History or evidence of any chronic disease",
    "sex": "MALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}